Skip to content
10-K

Annual Report

Cartesian Therapeutics, Inc. RNAC

0001453687-26-000064

← back to feed
Filed
Mar 9, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Feb 28, 2026 26.51M sh
Shares Diluted FY 2025 · Dec 31, 2025 25.97M sh
Shares Diluted FY 2025 · Dec 31, 2024 17.36M sh
Capex FY 2025 · Dec 31, 2025 $5.45M
Capex FY 2025 · Dec 31, 2024 $9.09M
Operating Cash Flow FY 2025 · Dec 31, 2025 −$73.94M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$23.67M
Cash And Equivalents FY 2025 · Dec 31, 2025 $125.14M
Cash And Equivalents FY 2025 · Dec 31, 2024 $212.61M
Stockholders Equity FY 2025 · Dec 31, 2025 −$126.24M
Stockholders Equity FY 2025 · Dec 31, 2024 −$6.8M
Stockholders Equity FY 2025 · Dec 31, 2023 −$440.18M
Current Liabilities FY 2025 · Dec 31, 2025 $14.94M
Current Liabilities FY 2025 · Dec 31, 2024 $22.98M
Total Liabilities FY 2025 · Dec 31, 2025 $422.65M
Total Liabilities FY 2025 · Dec 31, 2024 $441.83M
Current Assets FY 2025 · Dec 31, 2025 $129.28M
Current Assets FY 2025 · Dec 31, 2024 $216.63M
Total Assets FY 2025 · Dec 31, 2025 $296.41M
Total Assets FY 2025 · Dec 31, 2024 $435.02M
Eps Diluted FY 2025 · Dec 31, 2025 −$5.02
Eps Diluted FY 2025 · Dec 31, 2024 −$4.49
Eps Basic FY 2025 · Dec 31, 2025 −$5.02
Eps Basic FY 2025 · Dec 31, 2024 −$4.48
Sga Expense FY 2025 · Dec 31, 2025 $31.47M
Sga Expense FY 2025 · Dec 31, 2024 $30.13M
Rd Expense FY 2025 · Dec 31, 2025 $58.03M
Rd Expense FY 2025 · Dec 31, 2024 $45.11M
Net Income FY 2025 · Dec 31, 2025 −$130.3M
Net Income FY 2025 · Dec 31, 2024 −$77.42M
Operating Income FY 2025 · Dec 31, 2025 −$143.41M
Operating Income FY 2025 · Dec 31, 2024 −$43.9M
Revenue FY 2025 · Dec 31, 2025 $400K
Revenue FY 2025 · Dec 31, 2024 $38.28M